Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose isotretinoin versus itraconazole for moderate to severe seborrheic dermatitis
ACTRN12626000021370Phase 2Completed
- Sponsor
- PNS Shifa
- Start
- Jul 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in seborrheic dermatitis (SD) comparing Low-dose oral isotretinoin with Oral itraconazole (2 arms). Primary endpoint: Composite efficacy and safety primary endpoint. Started Jul 2025; status: completed.
02
Drugs
isotretinoinitraconazole
03
Conditions
seborrheic dermatitis (SD)
Beyond the preview
Go deeper on ACTRN12626000021370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000021370.